The ruling means that small-scale compounders must immediately stop making their versions of Novo’s Ozempic and Wegovy, while ...

A judge denied compounders' request to keep making off-brand Wegovy and Ozempic after the FDA removed semaglutide from its shortage list.

"We are pleased the court has rejected the compounders' attempts to undermine FDA's data-based decision that the shortage" of ...

Novo Nordisk's collaboration with telehealth providers offers semaglutide at $499/month, enhancing access for self-paying ...

Compounded versions of Novo Nordisk’s Wegovy and Ozempic will need ... pharmacies can’t keep making their products as the legal process continues. The April 24 order by U.S. District Court ...

A federal judge April 24 rejected a bid by compounding pharmacies to continue selling less expensive copies of semaglutide, Novo Nordisk's blockbuster ... through the legal process and in ...

Novo Nordisk (NVO ... through the legal process and in discussions with the FDA. Compounders and telehealth providers have continued their offerings for both Novo's semaglutide and Eli Lilly's ...

"We are pleased the court has rejected the compounders' attempts to undermine FDA's data-based decision that the shortage" of semaglutide is resolved, said Steve Benz, Novo Nordisk's corporate ...